FDA issued a Warning Letter to Sunrise Pharmaceutical, Inc. on 1/14/2010 for a previous inspection.
483 Sunrise Pharmaceutical Jun 2017

483 Sunrise Pharmaceutical Jun 2017

Jogy George FDA, Zhongren Wu FDA$119.00 - Available Now

FDA investigators audited the Sunrise Pharmaceutical - Rahway, NJ, United States facility and issued inspectional observations (via FDA 483) on 22 Jun 2017.

Product details

  • Category: Human Drugs
  • Inspection end: 22 Jun 2017
  • Location: Rahway, United States
  • FEI: 3004813394
Add To Cart